1.Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro-oncology 2014, 16 Suppl 4:iv1–63.
2.Kaza N, Kohli L, Roth KA: Autophagy in brain tumors: a new target for therapeutic intervention. Brain pathology (Zurich, Switzerland) 2012, 22(1):89–98.
3.Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S: Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell death and differentiation 2004, 11(4):448–457.
4.Ito H, Daido S, Kanzawa T, Kondo S, Kondo Y: Radiation-induced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells. International journal of oncology 2005, 26(5):1401–1410.
5.Miracco C, Cosci E, Oliveri G, Luzi P, Pacenti L, Monciatti I, Mannucci S, De Nisi MC, Toscano M, Malagnino V et al: Protein and mRNA expression of autophagy gene Beclin 1 in human brain tumours. International journal of oncology 2007, 30(2):429–436.
6.Huang X, Bai HM, Chen L, Li B, Lu YC: Reduced expression of LC3B-II and Beclin 1 in glioblastoma multiforme indicates a down-regulated autophagic capacity that relates to the progression of astrocytic tumors. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia 2010, 17(12):1515–1519.
7.Aoki H, Kondo Y, Aldape K, Yamamoto A, Iwado E, Yokoyama T, Hollingsworth EF, Kobayashi R, Hess K, Shinojima N et al: Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. Autophagy 2008, 4(4):467–475.
8.Pirtoli L, Cevenini G, Tini P, Vannini M, Oliveri G, Marsili S, Mourmouras V, Rubino G, Miracco C: The prognostic role of Beclin 1 protein expression in high-grade gliomas. Autophagy 2009, 5(7):930–936.
9.Garcia-Santos G, Antolin I, Herrera F, Martin V, Rodriguez-Blanco J, del Pilar Carrera M, Rodriguez C: Melatonin induces apoptosis in human neuroblastoma cancer cells. Journal of pineal research 2006, 41(2):130–135.
10.Martin-Renedo J, Mauriz JL, Jorquera F, Ruiz-Andres O, Gonzalez P, Gonzalez-Gallego J: Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. Journal of pineal research 2008, 45(4):532–540.
11.Hill SM, Blask DE: Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF–7) in culture. Cancer research 1988, 48(21):6121–6126.
12.Cos S, Fernandez R, Guezmes A, Sanchez-Barcelo EJ: Influence of melatonin on invasive and metastatic properties of MCF–7 human breast cancer cells. Cancer research 1998, 58(19):4383–4390.
13.Marelli MM, Limonta P, Maggi R, Motta M, Moretti RM: Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells. The Prostate 2000, 45(3):238–244.
14.Sainz RM, Mayo JC, Tan DX, Leon J, Manchester L, Reiter RJ: Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. The Prostate 2005, 63(1):29–43.
15.Sainz RM, Mayo JC, Tan DX, Lopez-Burillo S, Natarajan M, Reiter RJ: Antioxidant activity of melatonin in Chinese hamster ovarian cells: changes in cellular proliferation and differentiation. Biochemical and biophysical research communications 2003, 302(3):625–634.
16.Zhang HM, Zhang Y: Melatonin: a well-documented antioxidant with conditional pro-oxidant actions. Journal of pineal research 2014, 57(2):131–146.
17.Blask DE, Sauer LA, Dauchy RT, Holowachuk EW, Ruhoff MS, Kopff HS: Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer research 1999, 59(18):4693–4701.
18.Xi SC, Siu SW, Fong SW, Shiu SY: Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. The Prostate 2001, 46(1):52–61.
19.Bizzarri M, Proietti S, Cucina A, Reiter RJ: Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert opinion on therapeutic targets 2013, 17(12):1483–1496.
20.Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, Maestroni G: Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 1996, 53(1):43–46.
21.Motilva V, Garcia-Maurino S, Talero E, Illanes M: New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin. Journal of pineal research 2011, 51(1):44–60.
22.Hong Y, Won J, Lee Y, Lee S, Park K, Chang KT, Hong Y: Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells. Journal of pineal research 2014, 56(3):264–274.
23.Trivedi PP, Jena GB, Tikoo KB, Kumar V: Melatonin modulated autophagy and Nrf2 signaling pathways in mice with colitis-associated colon carcinogenesis. Molecular carcinogenesis 2015.
24.Liu C, Jia Z, Zhang X, Hou J, Wang L, Hao S, Ruan X, Yu Z, Zheng Y: Involvement of melatonin in autophagy-mediated mouse hepatoma H22 cell survival. International immunopharmacology 2012, 12(2):394–401.
25.Katayama M, Kawaguchi T, Berger MS, Pieper RO: DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell death and differentiation 2007, 14(3):548–558.
26.Zhao H, Cai Y, Santi S, Lafrenie R, Lee H: Chloroquine-mediated radiosensitization is due to the destabilization of the lysosomal membrane and subsequent induction of cell death by necrosis. Radiation research 2005, 164(3):250–257.
27.Feng Z, Zhang H, Levine AJ, Jin S: The coordinate regulation of the p53 and mTOR pathways in cells. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(23):8204–8209.
28.Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J et al: Phase II study of CCI–779 in patients with recurrent glioblastoma multiforme. Investigational new drugs 2005, 23(4):357–361.
29.Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF et al: Phase II trial of temsirolimus (CCI–779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2005, 23(23):5294–5304.
30.Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J et al: A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 2014, 10(8):1359–1368.
31.Martin V, Sanchez-Sanchez AM, Puente-Moncada N, Gomez-Lobo M, Alvarez-Vega MA, Antolin I, Rodriguez C: Involvement of autophagy in melatonin-induced cytotoxicity in glioma-initiating cells. Journal of pineal research 2014, 57(3):308–316.
32.Zhuang W, Li B, Long L, Chen L, Huang Q, Liang Z: Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity. International journal of cancer Journal international du cancer 2011, 129(11):2720–2731.
33.Ueda Y, Wei FY, Hide T, Michiue H, Takayama K, Kaitsuka T, Nakamura H, Makino K, Kuratsu J, Futaki S et al: Induction of autophagic cell death of glioma-initiating cells by cell-penetrating D-isomer peptides consisting of Pas and the p53 C-terminus. Biomaterials 2012, 33(35):9061–9069.
34.Kast RE: Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancers. Contemporary oncology (Poznan, Poland) 2015, 19(2):157–162.
35.Albert L, Karsy M, Murali R, Jhanwar-Uniyal M: Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme. Cancer genomics & proteomics 2009, 6(5):255–261.
36.Martin V, Herrera F, Carrera-Gonzalez P, Garcia-Santos G, Antolin I, Rodriguez-Blanco J, Rodriguez C: Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer research 2006, 66(2):1081–1088.
37.Kimball SR, Abbas A, Jefferson LS: Melatonin represses oxidative stress-induced activation of the MAP kinase and mTOR signaling pathways in H4IIE hepatoma cells through inhibition of Ras. Journal of pineal research 2008, 44(4):379–386.
38.Kongsuphol P, Mukda S, Nopparat C, Villarroel A, Govitrapong P: Melatonin attenuates methamphetamine-induced deactivation of the mammalian target of rapamycin signaling to induce autophagy in SK-N-SH cells. Journal of pineal research 2009, 46(2):199–206.
39.Zheng Y, Hou J, Liu J, Yao M, Li L, Zhang B, Zhu H, Wang Z: Inhibition of autophagy contributes to melatonin-mediated neuroprotection against transient focal cerebral ischemia in rats. Journal of pharmacological sciences 2014, 124(3):354–364.
40.Xiao W, Xiong Z, Xiong W, Yuan C, Xiao H, Ruan H, Song Z, Wang C, Bao L, Cao Q et al: Melatonin/PGC1A/UCP1 promotes tumor slimming and represses tumor progression by initiating autophagy and lipid browning. (1600–079X (Electronic)).
41.Coto-Montes A, Boga JA, Rosales-Corral S, Fuentes-Broto L, Tan DX, Reiter RJ: Role of melatonin in the regulation of autophagy and mitophagy: a review. Molecular and cellular endocrinology 2012, 361(1–2):12–23.
42.Liu YJ, Meng FT, Wang LL, Zhang LF, Cheng XP, Zhou JN: Apolipoprotein E influences melatonin biosynthesis by regulating NAT and MAOA expression in C6 cells. Journal of pineal research 2012, 52(4):397–402.